Browse PPARG

Summary
SymbolPPARG
Nameperoxisome proliferator-activated receptor gamma
Aliases PPARG1; PPARG2; NR1C3; PPARgamma; peroxisome proliferative activated receptor, gamma; CIMT1; GLM1; NR1C31; P ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=Redistributed from the nucleus to the cytosol through a MAP2K1/MEK1-dependent manner. NOCT enhances its nuclear translocation.
Domain PF00104 Ligand-binding domain of nuclear hormone receptor
PF12577 PPAR gamma N-terminal region
PF00105 Zinc finger
Function

Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity). ; FUNCTION: (Microbial infection) Upon treatment with M.tuberculosis or its lipoprotein LpqH, phosphorylation of MAPK p38 and IL-6 production are modulated, probably via this protein.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001558 regulation of cell growth
GO:0001890 placenta development
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0001960 negative regulation of cytokine-mediated signaling pathway
GO:0002521 leukocyte differentiation
GO:0002526 acute inflammatory response
GO:0002573 myeloid leukocyte differentiation
GO:0002673 regulation of acute inflammatory response
GO:0002674 negative regulation of acute inflammatory response
GO:0002683 negative regulation of immune system process
GO:0003013 circulatory system process
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006631 fatty acid metabolic process
GO:0006820 anion transport
GO:0006869 lipid transport
GO:0006909 phagocytosis
GO:0006911 phagocytosis, engulfment
GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0007507 heart development
GO:0007584 response to nutrient
GO:0007623 circadian rhythm
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0009266 response to temperature stimulus
GO:0009409 response to cold
GO:0009612 response to mechanical stimulus
GO:0009755 hormone-mediated signaling pathway
GO:0009991 response to extracellular stimulus
GO:0010001 glial cell differentiation
GO:0010324 membrane invagination
GO:0010565 regulation of cellular ketone metabolic process
GO:0010712 regulation of collagen metabolic process
GO:0010713 negative regulation of collagen metabolic process
GO:0010720 positive regulation of cell development
GO:0010742 macrophage derived foam cell differentiation
GO:0010743 regulation of macrophage derived foam cell differentiation
GO:0010745 negative regulation of macrophage derived foam cell differentiation
GO:0010869 regulation of receptor biosynthetic process
GO:0010871 negative regulation of receptor biosynthetic process
GO:0010876 lipid localization
GO:0010878 cholesterol storage
GO:0010883 regulation of lipid storage
GO:0010885 regulation of cholesterol storage
GO:0010887 negative regulation of cholesterol storage
GO:0010888 negative regulation of lipid storage
GO:0010889 regulation of sequestering of triglyceride
GO:0010891 negative regulation of sequestering of triglyceride
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0014013 regulation of gliogenesis
GO:0014015 positive regulation of gliogenesis
GO:0014074 response to purine-containing compound
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015850 organic hydroxy compound transport
GO:0015908 fatty acid transport
GO:0015909 long-chain fatty acid transport
GO:0015918 sterol transport
GO:0016049 cell growth
GO:0019216 regulation of lipid metabolic process
GO:0019217 regulation of fatty acid metabolic process
GO:0019395 fatty acid oxidation
GO:0019915 lipid storage
GO:0021700 developmental maturation
GO:0030099 myeloid cell differentiation
GO:0030100 regulation of endocytosis
GO:0030224 monocyte differentiation
GO:0030258 lipid modification
GO:0030301 cholesterol transport
GO:0030308 negative regulation of cell growth
GO:0030522 intracellular receptor signaling pathway
GO:0030730 sequestering of triglyceride
GO:0031000 response to caffeine
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031348 negative regulation of defense response
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0031670 cellular response to nutrient
GO:0032102 negative regulation of response to external stimulus
GO:0032368 regulation of lipid transport
GO:0032371 regulation of sterol transport
GO:0032374 regulation of cholesterol transport
GO:0032409 regulation of transporter activity
GO:0032526 response to retinoic acid
GO:0032799 low-density lipoprotein receptor particle metabolic process
GO:0032800 receptor biosynthetic process
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0032963 collagen metabolic process
GO:0032964 collagen biosynthetic process
GO:0032965 regulation of collagen biosynthetic process
GO:0032966 negative regulation of collagen biosynthetic process
GO:0033002 muscle cell proliferation
GO:0033189 response to vitamin A
GO:0033197 response to vitamin E
GO:0033273 response to vitamin
GO:0033500 carbohydrate homeostasis
GO:0034341 response to interferon-gamma
GO:0034440 lipid oxidation
GO:0034694 response to prostaglandin
GO:0034695 response to prostaglandin E
GO:0035357 peroxisome proliferator activated receptor signaling pathway
GO:0035902 response to immobilization stress
GO:0036295 cellular response to increased oxygen levels
GO:0036296 response to increased oxygen levels
GO:0042063 gliogenesis
GO:0042180 cellular ketone metabolic process
GO:0042493 response to drug
GO:0042593 glucose homeostasis
GO:0042594 response to starvation
GO:0042752 regulation of circadian rhythm
GO:0042953 lipoprotein transport
GO:0043112 receptor metabolic process
GO:0043279 response to alkaloid
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043401 steroid hormone mediated signaling pathway
GO:0043434 response to peptide hormone
GO:0043627 response to estrogen
GO:0044236 multicellular organism metabolic process
GO:0044246 regulation of multicellular organismal metabolic process
GO:0044252 negative regulation of multicellular organismal metabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0044872 lipoprotein localization
GO:0045088 regulation of innate immune response
GO:0045165 cell fate commitment
GO:0045444 fat cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0045600 positive regulation of fat cell differentiation
GO:0045685 regulation of glial cell differentiation
GO:0045687 positive regulation of glial cell differentiation
GO:0045713 low-density lipoprotein particle receptor biosynthetic process
GO:0045807 positive regulation of endocytosis
GO:0045824 negative regulation of innate immune response
GO:0045834 positive regulation of lipid metabolic process
GO:0045862 positive regulation of proteolysis
GO:0045923 positive regulation of fatty acid metabolic process
GO:0045926 negative regulation of growth
GO:0046320 regulation of fatty acid oxidation
GO:0046321 positive regulation of fatty acid oxidation
GO:0046942 carboxylic acid transport
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048147 negative regulation of fibroblast proliferation
GO:0048469 cell maturation
GO:0048511 rhythmic process
GO:0048545 response to steroid hormone
GO:0048608 reproductive structure development
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048662 negative regulation of smooth muscle cell proliferation
GO:0048709 oligodendrocyte differentiation
GO:0048713 regulation of oligodendrocyte differentiation
GO:0048714 positive regulation of oligodendrocyte differentiation
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0050764 regulation of phagocytosis
GO:0050766 positive regulation of phagocytosis
GO:0050769 positive regulation of neurogenesis
GO:0050777 negative regulation of immune response
GO:0050872 white fat cell differentiation
GO:0051052 regulation of DNA metabolic process
GO:0051053 negative regulation of DNA metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051235 maintenance of location
GO:0051348 negative regulation of transferase activity
GO:0051962 positive regulation of nervous system development
GO:0051972 regulation of telomerase activity
GO:0051974 negative regulation of telomerase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0055088 lipid homeostasis
GO:0055093 response to hyperoxia
GO:0055094 response to lipoprotein particle
GO:0055098 response to low-density lipoprotein particle
GO:0060099 regulation of phagocytosis, engulfment
GO:0060100 positive regulation of phagocytosis, engulfment
GO:0060330 regulation of response to interferon-gamma
GO:0060331 negative regulation of response to interferon-gamma
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0060334 regulation of interferon-gamma-mediated signaling pathway
GO:0060336 negative regulation of interferon-gamma-mediated signaling pathway
GO:0060627 regulation of vesicle-mediated transport
GO:0060694 regulation of cholesterol transporter activity
GO:0060759 regulation of response to cytokine stimulus
GO:0060761 negative regulation of response to cytokine stimulus
GO:0060850 regulation of transcription involved in cell fate commitment
GO:0061458 reproductive system development
GO:0070482 response to oxygen levels
GO:0071229 cellular response to acid chemical
GO:0071295 cellular response to vitamin
GO:0071300 cellular response to retinoic acid
GO:0071306 cellular response to vitamin E
GO:0071346 cellular response to interferon-gamma
GO:0071375 cellular response to peptide hormone stimulus
GO:0071379 cellular response to prostaglandin stimulus
GO:0071380 cellular response to prostaglandin E stimulus
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071453 cellular response to oxygen levels
GO:0071455 cellular response to hyperoxia
GO:0071496 cellular response to external stimulus
GO:0071897 DNA biosynthetic process
GO:0072343 pancreatic stellate cell proliferation
GO:0090077 foam cell differentiation
GO:0099024 plasma membrane invagination
GO:1901558 response to metformin
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901654 response to ketone
GO:1901655 cellular response to ketone
GO:1903131 mononuclear cell differentiation
GO:1905153 regulation of membrane invagination
GO:1905155 positive regulation of membrane invagination
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000229 regulation of pancreatic stellate cell proliferation
GO:2000230 negative regulation of pancreatic stellate cell proliferation
GO:2000278 regulation of DNA biosynthetic process
GO:2000279 negative regulation of DNA biosynthetic process
GO:2001056 positive regulation of cysteine-type endopeptidase activity
Molecular Function GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0003682 chromatin binding
GO:0003707 steroid hormone receptor activity
GO:0003713 transcription coactivator activity
GO:0004879 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding
GO:0004953 icosanoid receptor activity
GO:0004954 prostanoid receptor activity
GO:0004955 prostaglandin receptor activity
GO:0005504 fatty acid binding
GO:0008134 transcription factor binding
GO:0008144 drug binding
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
GO:0030331 estrogen receptor binding
GO:0030374 ligand-dependent nuclear receptor transcription coactivator activity
GO:0031406 carboxylic acid binding
GO:0033293 monocarboxylic acid binding
GO:0033613 activating transcription factor binding
GO:0035257 nuclear hormone receptor binding
GO:0035258 steroid hormone receptor binding
GO:0036041 long-chain fatty acid binding
GO:0042805 actinin binding
GO:0042974 retinoic acid receptor binding
GO:0043168 anion binding
GO:0046965 retinoid X receptor binding
GO:0050542 icosanoid binding
GO:0050543 icosatetraenoic acid binding
GO:0050544 arachidonic acid binding
GO:0051393 alpha-actinin binding
GO:0051427 hormone receptor binding
GO:0098531 transcription factor activity, direct ligand regulated sequence-specific DNA binding
Cellular Component GO:0005667 transcription factor complex
GO:0044798 nuclear transcription factor complex
GO:0090575 RNA polymerase II transcription factor complex
> KEGG and Reactome Pathway
 
KEGG hsa03320 PPAR signaling pathway
hsa04152 AMPK signaling pathway
hsa04380 Osteoclast differentiation
Reactome R-HSA-1266738: Developmental Biology
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-383280: Nuclear Receptor transcription pathway
R-HSA-1989781: PPARA activates gene expression
R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
Summary
SymbolPPARG
Nameperoxisome proliferator-activated receptor gamma
Aliases PPARG1; PPARG2; NR1C3; PPARgamma; peroxisome proliferative activated receptor, gamma; CIMT1; GLM1; NR1C31; P ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PPARG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PPARG and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25261236Breast CarcinomaInhibit immunityIn this study, we show that DCs isolated from patients with metastatic or locally advanced breast cancer express high levels of the adiponectin receptors AdipoR1 and AdipoR2, which are sufficient to blunt antitumor immunity. AdipoR1 stimulated IL10 production by activating the AMPK and MAPKp38 pathways, whereas AdipoR2 modified inflammatory processes by activating the COX-2 and PPARγ pathways. Stimulation of these pathways was sufficient to block activation of NF-κB in DC, thereby attenuating their ability to stimulate antigen-specific T-cell responses.
23493799MelanomaPromote immunityPeroxisome Proliferator-Activated Receptor gamma is involved in this statin-induced MICA overexpression, which is independent of Ras and Rho GTPase signaling pathways.
24957461Ovarian Dermoid Cyst with MelanomaPromote immunityInhibition of p38 MAPK in DCs lowers expression of PPARγ, activating p50 and upregulating OX40L expression in DCs.
29669721B16 Malignant MelanomaPromote immunityPeroxisome proliferator activated receptor-γ (PPARγ) is a lipid-activated nuclear receptor that promotes immune tolerance through effects on macrophages, dendritic cells (DCs), and regulatory T cells (Tregs).
28740126Bladder CarcinomaInhibit immunityHere, we report that the PPARγ/RXRα pathway constitutes a tumor-intrinsic mechanism underlying immune evasion in MIBC. Immune cell-infiltration is controlled by activated PPARγ/RXRα that inhibits expression/secretion of inflammatory cytokines. Knockdown of PPARγ or RXRα and pharmacological inhibition of PPARγ significantly increase cytokine expression suggesting therapeutic approaches to reviving immunosurveillance and sensitivity to immunotherapies.
29721374Traditional Serrated AdenomaPromote immunityPPARγ-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice. Treatment of mutant KRASG12V mice with the PPARγ-agonist rosiglitazone augmented M1 macrophage numbers, reduced IL4 expression and diminished polyp load in mice. Rosiglitazone also promoted M1 polarisation of human THP1-derived macrophages and decreased Il4 mRNA in isolated murine lymphocytes.
Summary
SymbolPPARG
Nameperoxisome proliferator-activated receptor gamma
Aliases PPARG1; PPARG2; NR1C3; PPARgamma; peroxisome proliferative activated receptor, gamma; CIMT1; GLM1; NR1C31; P ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PPARG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPPARG
Nameperoxisome proliferator-activated receptor gamma
Aliases PPARG1; PPARG2; NR1C3; PPARgamma; peroxisome proliferative activated receptor, gamma; CIMT1; GLM1; NR1C31; P ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PPARG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5650.125
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7080.473
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4520.5
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2340.693
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4950.797
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0860.969
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2440.588
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7340.451
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3370.761
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4870.654
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9020.588
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.140.568
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PPARG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPPARG
Nameperoxisome proliferator-activated receptor gamma
Aliases PPARG1; PPARG2; NR1C3; PPARgamma; peroxisome proliferative activated receptor, gamma; CIMT1; GLM1; NR1C31; P ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPARG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPPARG
Nameperoxisome proliferator-activated receptor gamma
Aliases PPARG1; PPARG2; NR1C3; PPARgamma; peroxisome proliferative activated receptor, gamma; CIMT1; GLM1; NR1C31; P ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPARG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPARG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPPARG
Nameperoxisome proliferator-activated receptor gamma
Aliases PPARG1; PPARG2; NR1C3; PPARgamma; peroxisome proliferative activated receptor, gamma; CIMT1; GLM1; NR1C31; P ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPARG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPPARG
Nameperoxisome proliferator-activated receptor gamma
Aliases PPARG1; PPARG2; NR1C3; PPARgamma; peroxisome proliferative activated receptor, gamma; CIMT1; GLM1; NR1C31; P ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PPARG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPPARG
Nameperoxisome proliferator-activated receptor gamma
Aliases PPARG1; PPARG2; NR1C3; PPARgamma; peroxisome proliferative activated receptor, gamma; CIMT1; GLM1; NR1C31; P ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PPARG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPPARG
Nameperoxisome proliferator-activated receptor gamma
Aliases PPARG1; PPARG2; NR1C3; PPARgamma; peroxisome proliferative activated receptor, gamma; CIMT1; GLM1; NR1C31; P ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PPARG collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PPARG.
ID Name Drug Type Targets #Targets
DB00132Alpha-Linolenic AcidSmall MoleculeELOVL4, FADS1, FADS2, NR1H4, PPARA, PPARD, PPARG, RXRA, SLC8A1, TR ......10
DB00159IcosapentSmall MoleculeACSL3, ACSL4, FADS1, FFAR1, PPARA, PPARD, PPARG, PTGS1, PTGS2, SLC ......11
DB00197TroglitazoneSmall MoleculeACSL4, ESRRA, ESRRG, GSTP1, PPARA, PPARD, PPARG, SERPINE1, SLC29A19
DB00244MesalazineSmall MoleculeALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS27
DB00313Valproic AcidSmall MoleculeABAT, ACADSB, ALDH5A1, HDAC2, HDAC9, OGDH, PPARA, PPARD, PPARG, SC ......23
DB00328IndomethacinSmall MoleculeAKR1C3, GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS29
DB00412RosiglitazoneSmall MoleculeACSL4, PPARA, PPARD, PPARG, RXRA, RXRB, RXRG7
DB00573FenoprofenSmall MoleculePPARA, PPARG, PTGS1, PTGS24
DB00731NateglinideSmall MoleculeABCC8, PPARG2
DB00795SulfasalazineSmall MoleculeACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC7A11, ......10
DB00912RepaglinideSmall MoleculeABCC8, PPARG2
DB00966TelmisartanSmall MoleculeAGTR1, PPARG2
DB01014BalsalazideSmall MoleculeALOX5, PPARG, PTGS1, PTGS24
DB01039FenofibrateSmall MoleculeNR1I2, PPARA, PPARD, PPARG4
DB01050IbuprofenSmall MoleculeBCL2, CFTR, FABP2, PLAT, PPARA, PPARG, PTGS1, PTGS2, SLC15A1, THBD10
DB01067GlipizideSmall MoleculeABCC8, PPARG2
DB01118AmiodaroneSmall MoleculeADRB1, CACNA1H, CACNA2D2, KCNH2, PPARG, THRA, THRB7
DB01132PioglitazoneSmall MoleculeMAOB, PPARA, PPARD, PPARG4
DB01252MitiglinideSmall MoleculeABCC8, PPARG2
DB01393BezafibrateSmall MoleculeNR1I2, PPARA, PPARD, PPARG, RXRA, RXRB, RXRG7
DB02266Flufenamic AcidSmall MoleculeAKR1C3, AR, PPARA, PPARG, PTGS1, PTGS26
DB02709ResveratrolSmall MoleculeAHR, AKT1, ALOX15, ALOX5, APP, CBR1, CLEC14A, CSNK2A1, ESR1, ITGA5 ......25
DB02746Phthalic AcidSmall MoleculeESR1, ESR2, PGR, PPARA, PPARD, PPARG, RXRA, RXRB, RXRG9
DB03600Capric acidSmall MoleculeFURIN, GLTP, PPARG3
DB03756DoconexentSmall MoleculePPARA, PPARG, RXRA, RXRB, RXRG, SREBF16
DB04224Oleic AcidSmall MoleculeGLTP, PMP2, PPARA, PPARD, PPARG, RXRA6
DB04270(S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic AcidSmall MoleculePPARG1
DB046892-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACIDSmall MoleculePPARG1
DB04971ReglixaneSmall MoleculePPARA, PPARG2
DB05187ElafibranorSmall MoleculePPARA, PPARD, PPARG3
DB05490T131Small MoleculePPARG1
DB05854CLX-0921Small MoleculePPARG1
DB06510MuraglitazarSmall MoleculePPARA, PPARG2
DB06521ErtiprotafibSmall MoleculeIKBKB, PPARA, PPARG, PTPN14
DB06533RagaglitazarSmall MoleculePPARA, PPARG2
DB06536TesaglitazarSmall MoleculePPARA, PPARG2
DB06908(2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACIDSmall MoleculeNCOA1, PPARG2
DB06926(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acidSmall MoleculePPARG1
DB070532-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACIDSmall MoleculePPARG1
DB07111(4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acidSmall MoleculePPARG1
DB07172(5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acidSmall MoleculePPARG1
DB07208(8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acidSmall MoleculePPARG1
DB07209(8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acidSmall MoleculePPARG1
DB07302(9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acidSmall MoleculePPARG1
DB07509difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boronSmall MoleculePPARG1
DB07675(2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACIDSmall MoleculePPARG1
DB077233-(5-methoxy-1H-indol-3-yl)propanoic acidSmall MoleculePPARG1
DB07724IndeglitazarSmall MoleculeNCOA1, PPARA, PPARD, PPARG4
DB07842(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acidSmall MoleculePPARG1
DB078632-chloro-5-nitro-N-phenylbenzamideSmall MoleculeNCOA2, PPARG, RXRA3
DB08121(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acidSmall MoleculePPARG1
DB083023-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acidSmall MoleculePPARG1
DB084022-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACIDSmall MoleculeNCOA2, PPARG, RXRA3
DB08435(5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acidSmall MoleculePPARG1
DB085603-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDESmall MoleculePPARG1
DB08604TriclosanSmall MoleculeAR, NR1I2, NR1I3, PPARG, TPO5
DB08760(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acidSmall MoleculePPARG1
DB08915AleglitazarSmall MoleculeNCOA1, PPARA, PPARG3
DB09006ClinofibrateSmall MoleculePPARA, PPARD, PPARG3
DB09061CannabidiolSmall MoleculeCACNA1G, CACNA1H, CACNA1I, CHRNA7, CNR1, CNR2, GLRA1, GLRA1, GLRA3 ......25
DB09198LobeglitazoneSmall MoleculePPARG1
DB09201CiglitazoneSmall MoleculePPARG1
DB09213DexibuprofenSmall MoleculeBCL2, CFTR, FABP2, PLAT, PPARG, PTGS1, PTGS2, THBD8
DB11133Omega-3 fatty acidsSmall MoleculePPARA, PPARG, SREBF13
DB11672CurcuminSmall MoleculeABCC5, CBR1, GSTP1, PPARG, VDR5
DB11811ArhalofenateSmall MoleculePPARG1
DB12662NaveglitazarSmall MoleculePPARG1
DB13873Fenofibric acidSmall MoleculeNR1I2, PPARA, PPARD, PPARG4